Current Oncology, Volume 18, Issue 6

Lymphedema in Canada: A Qualitative Study to Help Develop a Clinical, Research, and Education Strategy [...]

AMO has participated on advisory boards for AstraZeneca, Celgene Corporation, and Sanofi–Aventis [...]

Is the age of onset of breast cancer in women with a BRCA1 or BRCA2 mutation decreasing?[...].

Cancer contributes to approximately 13% (7.4 million) of all deaths worldwide 1, making cancer the leading cause of death across the globe. Based on Canadian data, 29% of deaths each year are estimated to be related to cancer 2 [...].

Consumption of dietary carcinogens contributes to the prevalence of cancer in society [...].

In addition to chemotherapeutics, cancer patients often take a variety of medications for reasons related and unrelated to their underlying cancer [...].

Objective: Nationally, efforts to implement an innovation in cancer surgery—a Web-based synoptic reporting tool—are ongoing in five provinces. The objective of the present study was to identify the key multilevel factors influencing implementation an...

Objectives: Febrile neutropenia is considered an oncologic emergency, for which prompt initiation of antibiotics is essential. Methods: We conducted a retrospective cohort study for the 2006 calendar year involving all adult oncology patients present...

Background: Although arthralgia is a known adverse effect of aromatase inhibitor (ai) treatment in postmenopausal breast cancer patients, few studies have carried out a comprehensive evaluation of the nature, onset, and incidence of musculoskeletal (...

The inaugural Canadian Cardiac Oncology Network conference was held at the Ottawa Convention Centre, Ottawa, Ontario, May 13, 2011. The learning objectives of the meeting were to: 1. understand and appreciate the importance of cardiac toxicity in the...